{"nctId":"NCT01590771","briefTitle":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","startDateStruct":{"date":"2012-07-09","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":498,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Gliclazide","Drug: Glimepiride","Drug: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Gliclazide","Drug: Glimepiride","Drug: Metformin"]}],"interventions":[{"name":"Sitagliptin","otherNames":["Januvia®","MK-0431"]},{"name":"Placebo","otherNames":[]},{"name":"Gliclazide","otherNames":[]},{"name":"Glimepiride","otherNames":[]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* has T2DM\n* is currently on a stable regimen of gliclazide or glimepiride, either alone or in combination with metformin for ≥ 10 weeks\n* has a Visit 1/Screening HbA1C between 7.5% and 11.0%\n* is a male, or a female who is highly unlikely to conceive during the study and for 14 days after the last dose of study medication\n\nExclusion Criteria:\n\n* has a history of type 1 diabetes mellitus or a history of ketoacidosis\n* has been treated with any antihyperglycemic therapies other than a sulfonylurea (alone or with metformin) within the prior 12 weeks or has ever\n\nbeen treated with a dipeptidyl peptidase-4 inhibitor or a glucagon-like peptide-1 mimetic or analogue\n\n* has a history of intolerance or hypersensitivity, or has any contraindication to sitagliptin, gliclazide/glimepiride, or metformin\n* is on a weight loss program and not in the maintenance phase, or has started a weight loss medication or has undergone bariatric surgery within 12 months\n* has undergone a surgical procedure within 4 weeks or has planned major surgery during the study\n* has a medical history of active liver disease\n* has had new or worsening signs or symptoms of coronary heart disease within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder\n* has a diagnosis of congestive heart failure with New York Heart Association Class III - IV cardiac status\n* has a systolic blood pressure ≥ 160 mmHg or a diastolic blood pressure ≥ 90 mmHg\n* has human immunodeficiency virus (HIV)\n* has severe peripheral vascular disease\n* is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks\n* has a history of malignancy ≤ 5 years before the study, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* has a clinically important hematological disorder (such as aplastic anemia,\n\nmyeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n* is pregnant or breast feeding, or is expecting to conceive or donate eggs during the study, including 14 days after the last dose of study medication\n* is a user of recreational or illicit drugs or has had a recent history of drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin","description":"A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":null},{"groupId":"OG001","value":"-0.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin","description":"This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.7","spread":null},{"groupId":"OG001","value":"-7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin","description":"This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.4","spread":"-29.1"},{"groupId":"OG001","value":"-7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin","description":"A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.86","spread":null},{"groupId":"OG001","value":"-0.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone","description":"A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.85","spread":null},{"groupId":"OG001","value":"-0.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin","description":"This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.4","spread":null},{"groupId":"OG001","value":"-6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone","description":"This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.5","spread":null},{"groupId":"OG001","value":"-11.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin","description":"This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.2","spread":null},{"groupId":"OG001","value":"-5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone","description":"This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.3","spread":null},{"groupId":"OG001","value":"-9.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced an Adverse Event","description":"An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":"An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":248},"commonTop":["Hypoglycaemia","Urinary tract infection","Hyperlipidaemia"]}}}